

Commonwealth of Massachusetts

MassHealth Drug Utilization Review Program
P.O. Box 2586

Worcester, MA 01613-2586

**Fax:** 1-877-208-7428 **Phone:** 1-800-745-7318

## **Strattera Prior Authorization Request**

First name

☐ home

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

PA is required for Strattera (atomoxetine). Additional information about which drugs require PA can be found within the MassHealth Drug List at **www.mass.gov/druglist**.

MassHealth member ID no.

Date of birth | Sex (Circle one.)

MI

nursing facility

## **Member information**

Member's place of residence

Last name

	Dose, frequency, and duration	Drug NDC (if known) or service code				
Strattera 10 mg Strattera 18 mg Strattera 25 mg Strattera 40 mg Strattera 60 mg Strattera 80 mg Strattera 100 mg	Note: The manufacturer recommends an initial dose of 0.5 mg/kg/day for children and adolescents weighing < 70 kg with a target dose of 1.2 mg/kg/day. The maximum dose is 1.4 mg/kg/day or 100 mg, whichever is lower. In patients weighing more than 70 kg, the recommended initial dose is 40 mg daily with a targeted dose up to 80 mg. Daily dose of Strattera should not exceed 100 mg.  Indication (Check one or all that apply.)  Attention Deficit Hyperactivity Disorder (ADHD)  Other (Explain.)					
nember under the care of a psychiatrist or be	ehavioral specialist?					
ame of psychiatrist or behavioral specialist _						
elephone no.:	_ Date of	ast visit:				
ase list all medications currently prescribed for	this member for this condition.					
ase describe your new treatment plan for mar	naging this member's condition, including discontinuation	of any medications as a result of the addi-				

PA-20 (Rev. 06/06) over ▶

## **Medication information** (cont.)

condition?		e methylphenidate class (	• ,			, ,	,
	Yes. Complete box A.	☐ No. Exp	lain why no	ot			
A. Drug name		Dates of use			Dose and free	quency	
id member expe	erience any of the following?	Adverse reaction	☐ Inadequ	uate response	Intolerance	e 🗆 Othe	er
Briefly describ	e details of adverse reaction, i	nadequate response, intole	erance, or o	other.			
las member tri	ed other medications in the a	amphetamine/dextroam	phetamin	e class (i.e., Add	erall or Dexedr	ine) to trea	t this conditio
Yes. Complete	e box B.	o. Explain why not.					
B. Drug name		Dates of use			Dose and free	quency	
id member expe	erience any of the following?	Adverse reaction	☐ Inadequ	uate response	☐ Intolerance	⊖ □ Othe	er
Briefly describ	e details of adverse reaction, i	nadequate response, intole	erance, or o	other.			
las member tri	ied other non-stimulant me	dications to treat this co	ondition?				
Yes. Complete	e box C.	o. Explain why not.					
Norma nama		Detec of wee			Daga and Coa		
. Drug name		Dates of use			Dose and free	quency	
Did member expe	erience any of the following?	Adverse reaction	☐ Inadequ	uate response	Intolerance	e 🗆 Othe	er
		_			☐ Intolerance	e 🗆 Othe	er
	erience any of the following? be details of adverse reaction, i	_			□ Intolerance	e 🗆 Othe	er
Briefly describ	e details of adverse reaction, i	nadequate response, intole	erance, or o	other.			
Briefly describ		nadequate response, intole	erance, or o	other.			
Briefly describ	e details of adverse reaction, i	nadequate response, intole	erance, or o	other.			
Briefly describ	e details of adverse reaction, i	nadequate response, intole ocumentation (e.g., copies o	erance, or o	records, office no		npleted FDA	
Briefly describ	e details of adverse reaction, i	nadequate response, intole	erance, or o	other.			
Briefly describ  Jote: You may be  harmacy  ame	e details of adverse reaction, i	nadequate response, intole ocumentation (e.g., copies o	erance, or o	records, office no		npleted FDA	
Briefly describ  Jote: You may be  harmacy  ame	e details of adverse reaction, i	nadequate response, intole ocumentation (e.g., copies o	erance, or o	records, office no		npleted FDA Fax no.	MedWatch for
Briefly describ  Jote: You may be  harmacy  ame  ddress	e details of adverse reaction, i	nadequate response, intole ocumentation (e.g., copies o	erance, or o	records, office no		npleted FDA Fax no.	MedWatch for
Briefly describ	e details of adverse reaction, i	nadequate response, intole locumentation (e.g., copies of Pharmacy provi	erance, or o	records, office no	otes, and/or cor	npleted FDA Fax no.	MedWatch for
Briefly describ	e details of adverse reaction, is asked to provide supporting differential information	nadequate response, intole locumentation (e.g., copies of Pharmacy provi	erance, or o	Telephone no.  ( )  City	otes, and/or cor	Fax no. ( ) State	MedWatch for
Briefly describ	e details of adverse reaction, is asked to provide supporting differential information	nadequate response, intole locumentation (e.g., copies of Pharmacy provi	erance, or o	Telephone no.  ( ) City  MassHealth pro	otes, and/or cor	Fax no.	MedWatch for
Briefly describ  Note: You may be  harmacy  lame  ddress	e details of adverse reaction, is asked to provide supporting differential information	nadequate response, intole locumentation (e.g., copies of Pharmacy provi	erance, or o	Telephone no.  ( )  City	otes, and/or cor	Fax no. ( ) State	MedWatch for